Unlike in the rest of the country, where intestinal ultrasound rarely is used in the clinic, in New York City, gastroenterologists at Mount Sinai Hospital have made IUS findings the “the fifth vital sign” for inflammatory bowel disease patient care, particularly to monitor disease. Now, new research from the institution and other centers is showing that the tool can identify patients with endoscopic recurrence and possibly predict disease outcomes and treatment response.
Trending
- State laws may be curbing private equity takeovers of physician group (STAT)
- AI Shows Promise Across Spectrum of GI Motility Diagnostics, Review Finds (GI & Endoscopy News)
- Simple mouth rinse may help detect stomach and colorectal cancer signals (Medical Xpress)
- Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs (MedCity News)
- Top AI in Endoscopy Companies Revolutionizing Real-Time Diagnostics and Intelligent Endoscopic Care (Fortune Business Insights)
- Rome V criteria capture more people with IBS, but a milder group (GI & Hepatology News)
- Real-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic Costs (Business Wire)
- FITs Offer Lowest Environmental Footprint Among CRC Screening Options (AJMC)
